Lifeward Ltd. · NASDAQ:LFWD
Lifeward — ReWalk Robotics — Investor Presentation (April 2024)
26 slides from Lifeward's investor presentation, Apr 3, 2024
Slide 1: Investor Presentation April 2024
Investor Presentation April 2024
Slide 2: Forward Looking Statements
we are partners in energy storage Forward Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1
Slide 3: Video link
https://youtu.be/-WC02eT-Yig
Slide 4: The Lifeward Mission
The Lifeward Mission: Our mission at Lifeward is to relentlessly drive innovation to change the lives of people with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love.
Slide 5: A Leader in Pioneering Life-Changing Solutions
5 A Leader in Pioneering Life-Changing Solutions Recent strategic achievements FDA approval of stairs / curb capability for the ReWalk exoskeleton Acquisition of AlterG, the initial innovator of Anti-Gravity Systems CMS establishes Medicare benefit category for exoskeletons First claim paid by Medic
Slide 6: A History of Innovative Firsts
A History of Innovative Firsts 6 First personal exoskeleton to market with FDA and CE approvals First commercial application of NASA-derived Differential Air Pressure Technology First to establish a listing for exoskeletons within the German Medical Device Directory First Anti-Gravity Treadmill to b
Slide 7: Product Portfolio
10 LIFEWARD Product Portfol
Slide 8: Innovation in Motion: Portfolio Overview
8 Innovation in Motion: Portfolio Overview ReWalk Personal Exoskeleton State-of-the-art technology that enables paralyzed individuals to access the health-related benefits of walking from the comfort of their home and community setting. AlterG Anti-Gravity System NASA-derived Differential Air Pressu
Slide 9: Our flagship product: ReWalk Personal Exoskeleton
9 Our flagship product ReWalk Personal Exoskeleton Unprecedented freedom – Only personal exoskeleton enabling ambulatory access to real-world environments, including locations with stairs or curbs Natural gait – Only personal exoskeleton with six adjustable degrees of freedom for more customizable,
Slide 10: Proven Health Benefits
Proven Health Benefits Health benefits reported by ReWalk users in a 2023 home-user survey8 Frequently reported benefits in literature include reductions in common comorbidities after SCI, including: Reduced spasticity Improved bowel/bladder function Reduced chronic pain Regular access to exoskeleto
Slide 11: Increasing Progress of Reimbursement/Coverage
Increasing Progress of Reimbursement/Coverage 9M US Veterans covered under VA Personal Exoskeleton policy since 2015. Over 225 systems covered through private and other insurance, on a case-by-case basis. Exoskeletons assigned to Medicare Brace benefit category effective Jan 1, 2024. First Medicare
Slide 12: SCI Market Potential to Be Determined by CMS Coverage
SCI Market Potential to Be Determined by CMS Coverage Potential Total Addressable Market US 15,416 Germany 2,064 Global 17,480 Potential TAM $1.75B US 296,0009 Germany 74,00010 Global 7.1 Million10 Prevalence of SCI Survivors Eligible Candidates11,12 Reimbursement Pathway13,14
Slide 13: AlterG Anti-Gravity Systems
13 AlterG Anti-Gravity Systems Broadening our impact to more individuals than ever before Expert & proven development – NASA-derived technology to reduce the effects of gravity during rehabilitation and recovery Precision Calibration – patented algorithms enable precise measurement and real-time ad
Slide 14: AlterG Market Potential
AlterG Market Potential Appropriate customer based on patient/athlete population and sufficient capital budget Potential Total Addressable Market US 14,000 Germany 3,500 Global 40,000 Potential TAM $1.2B Inpatient Facilities Outpatient Clinics Professional & Elite Sports US 1,15215 44,00016 1,400 Ge
Slide 15: Additional Complementary Product Lines
15 Additional Complementary Product Lines ReStore Exo-Suit for Stroke Rehabilitation Unique capabilities – only FDA and CE-cleared tool offering on-demand mechanical assistance to retrain post-stroke walking function during “push-off” (propulsion) Enhanced gait training – improves training specifici
Slide 16: Consolidation Strategy
v LIFEWARD Consolidation Strategy
Slide 17: Rehabilitation Technology Market Attractive for Further Consolidation
17 Rehabilitation Technology Market Attractive for Further Consolidation Fragmented industry with many small players Mostly private companies with limited access to capital Innovative technologies with distribution constraints Complementary products sold to the rehabilitation clinic or for home/comm
Slide 18: Key Attributes of AlterG Acquisition
Enhances Lifeward’s position as a leader in innovative physical medicine and rehabilitation technologies that enable mobility and wellness Strategy Adds novel technology – Differential Air Pressure – with proven commercial success and potential for further applications and growth Technology Creates
Slide 19: Perpetuating Cycle of Lead Generation
Perpetuating Cycle of Lead Generation 19 AlterG Anti-Gravity System MyoCycle Pro ReStore Exo-Suit MyoCycle Home Clinic Network for Patient Training ReWalk Personal Exoskeleton Patient Referrals from Clinical Customers Combined portfolio strengthens engagement with clinics, driving more patient refer
Slide 20: Deep and Talented Leadership Team
Deep and Talented Leadership Team 20 Larry JasinskiChief Executive Officer Mike LawlessChief Financial Officer Charles RemsbergChief Sales Officer Miri ParienteVice President, Operations, Regulatory & Quality David Hexner Vice President, Research & Development Ami KraftExecutive Advisor to the CEO A
Slide 21: Financial Summary
Financial Summary 21 Cash $28 million Cash & cash equivalents (as of December 31, 2023) Debt No debt Cash Runway Path to profitability by 2026 with existing cash balance Well-Positioned for Funding Internal Growth and Integration Strategy
Slide 22: 2024 Milestones & Catalysts
we are partners in energy storage 2024 Milestones & Catalysts Medicare benefit category for Personal Exoskeletons effective January 1, 2024 First Medicare claim paid for a ReWalk Personal Exoskeleton as a medically necessary device Established Medicare payment rate for Personal Exoskeletons New Prod
Slide 23: Lifeward is Well Positioned for Future Growth
Expanding addressable market in United States and Germany; first Medicare claims ongoing Lifeward is Well Positioned for Future Growth Large, growing and fragmented Rehabilitation Technology market with many attractive candidates for consolidation Fundamentally changes lives for individuals with phy
Slide 24: Thank You!
we are partners in energy storage THANK YOU!
Slide 25: References
we are partners in energy storage References References Tamburella et al. Journal of Neuroengineering and Rehabilitation (2022) Asselin et al., Arch Phys Med Rehab (2021) Gorman et al., J Clin Med (2021) Duddy et al., Sensors (2021) Shackleton et al., J Rehab Med (2019) Juszczak et al., Topics Spin
Slide 26: References (cont'd)
we are partners in energy storage References (cont’d) References (continued) MedPAC 2021 Report: www.medpac.gov/wp-content/uploads/2021/10/mar21_medpac_report_ch9_sec.pdf www.ibisworld.com/industry-statistics/number-of-businesses/physical-therapy-rehabilitation-centers-united-states/ (accessed Jan 2